PHARMACOKINETICS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN APPLIED SUBCUTANEOUSLY TO CHILDREN WITH CHRONIC-RENAL-FAILURE

被引:10
作者
BRAUN, A [1 ]
DING, R [1 ]
SEIDEL, C [1 ]
FIES, T [1 ]
KURTZ, A [1 ]
SCHARER, K [1 ]
机构
[1] UNIV HEIDELBERG,KINDERKLIN,SEKT PADIAT NEPHROL,NEUENHEIMER FELD 150,W-6900 HEIDELBERG,GERMANY
关键词
ANEMIA; CHRONIC RENAL FAILURE; ERYTHROPOIETIN; PHARMACOKINETICS;
D O I
10.1007/BF00861571
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The single-dose pharmacokinetics of recombinant human erythropoietin (rHuEPO) given SC was investigated in 20 patients aged 7-20 years at different stages of chronic renal failure. In a pilot study we confirmed the lower bioavailability of the drug in 2 children when given SC compared with the IV route (24% and 43%, respectively). Following administration of 4,000 units/M2, rHuEPO SC effective serum erythropoietin concentrations increased from a mean baseline level (+/-SD) of 23+/-13 units/l to a mean peak concentration of 265+/-123 units/l, which was reached after 14.3+/-9.4 h, followed by a slow decline until baseline values were attained at 72 h. Mean residence time was 30+/-9 h and mean elimination half-time 14.3+/-7 h. The single-dose kinetics of SC rHuEPO in children with different degrees of renal failure are comparable to those in adult patients. Possibly, the higher efficacy of SC rHuEPO in patients with renal anaemia compared with IV rHuEPO is related to its prolonged action.
引用
收藏
页码:61 / 64
页数:4
相关论文
共 31 条
[11]  
Boelaert J.R., Schurgers M.L., Matthys E.G., Belpaire F.M., Daneels R.F., De Cre M.J., Bogaert M.G., Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients, Perit Dial Int, 9, pp. 95-98, (1989)
[12]  
Kindler J., Eckardt K.U., Ehmer B., Jandeleit K., Kurtz A., Schreiber A., Scigalla P., Sieberth H.G., Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure, Nephrol Dial Transplant, 4, pp. 345-349, (1989)
[13]  
Salmonson T., Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin, Scand J Urol Nephrol, 129, pp. 1-66, (1990)
[14]  
Bommer J., Barth H.J., Zeier M., Mandelbaum A., Bommer G., Ritz E., Reichel H., Novack R., Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients, Contrib Nephrol, 88, pp. 136-143, (1991)
[15]  
McMacon L.P., Dawborn J.K., Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin, American Journal of Nephrology, 10, pp. 404-408, (1990)
[16]  
Egrie J.C., Eschbach J.W., McGuire T., Adaon J.W., Pharmacokinetics of recombinant human erythropoietin (rHuEPO) administered to haemodialysis patients (abstract), Kidney Int, 33, (1988)
[17]  
Cotes P.M., Pippard M.J., Reid C.D.L., Winearls C.G., Oliver D.O., Characterization of the anemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (rHuEPO): an investigation of the pharmacokinetics of intravenous erythropoietin and its effect on erythrokinetics, Q J Med, 70, pp. 113-137, (1989)
[18]  
Faulds D., Sorkin E.M., Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis, Drugs, 38, pp. 863-899, (1989)
[19]  
Eckardt K.U., Kurtz A., Hirth P., Scigalla P., Wieczorek L., Bauer C., Evaluation of the stability of human erythropoietin in samples for radioimmunoassay, Klin Wochenschr, 66, pp. 241-245, (1988)
[20]  
Eckardt K.U., Hartmann W., Vetter U., Pohlandt F., Burghardt R., Kurtz A., Serum immunoreactive erythropoietin of children in health and disease, Eur J Pediatr, 149, pp. 459-464, (1990)